WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more

Werfen Offers In-Booth Instrument Demonstrations and Educational Workshop

By LabMedica International staff writers
Posted on 22 Jul 2023

Image: The ACL TOP Family 50 Series systems is a breakthrough in hemostasis testing (Photo courtesy of Werfen)

Werfen (Barcelona, Spain) is offering in-booth demonstrations of its point-of-care and laboratory instruments, reagents, and data management solutions at AACC 2023. The company is also hosting an educational workshop focusing on the prevalence and impact of pre-analytical errors in point-of-care blood gas testing. Werfen is also hosting a press conference at the AACC to introduce and explain the company’s recent acquisition of Immucor, Inc. (Norcross, GA, USA).

Werfen provides a comprehensive and integrated range of products and services. From intensive care units to operating rooms, emergency departments to interventional radiology suites and cardiac catheterization labs, and central and satellite laboratories, the company’s testing solutions are designed to deliver quality results, quickly and simply, irrespective of the setting. At AACC 2023, Werfen is offering instrument demonstrations its wide range of systems, including the ACL TOP Family 50 Series, HemoCell Specialized Lab Automation, HemosIL assays, HemoHub Intelligent Data Manager; GEM Premier 5000, GEM Premier ChemSTAT, GEM Hemochron 100, ROTEM sigma, VerifyNow, GMweb Plus 500, Aptiva, BIO-FLASH, QUANTA-Lyser, QUANTA-Link; Echo Lumena, and NEO Iris. The company is also offering a virtual reality experience featuring customized layouts for HemoCell Lab Automation.

At AACC 2023, senior leaders from Werfen will introduce and explain the company’s recent acquisition of Immucor, an in vitro diagnostic company with strong global leadership in the clinical areas of transfusion and transplant. With the integration of Immucor, Werfen has expanded its presence in specialized diagnostics with seven technology centers and more than 7,000 employees worldwide. The company will continue to operate directly in 34 countries, and in more than 100 territories through distributors. Most importantly, Werfen can now offer its customers an even broader portfolio of products and solutions across hospital acute care settings, and contribute to the care of more patients around the world.

Related Links:
Werfen
Immucor, Inc.